Cargando…
A unique ligand‐steered strategy for CC chemokine receptor 2 homology modeling to facilitate structure‐based virtual screening
CC chemokine receptor 2 (CCR2) antagonists that disrupt CCR2/MCP‐1 interaction are expected to treat a variety of inflammatory and autoimmune diseases. The lack of CCR2 crystal structure limits the application of structure‐based drug design (SBDD) to this target. Although a few three‐dimensional the...
Autores principales: | Jin, Hongwei, Xia, Jie, Liu, Zhenming, Wang, Xiang Simon, Zhang, Liangren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048943/ https://www.ncbi.nlm.nih.gov/pubmed/33386704 http://dx.doi.org/10.1111/cbdd.13820 |
Ejemplares similares
-
An Unbiased
Method To Build Benchmarking Sets for
Ligand-Based Virtual Screening and its Application To GPCRs
por: Xia, Jie, et al.
Publicado: (2014) -
Discovery of novel multidrug resistance protein 4 (MRP4) inhibitors as active agents reducing resistance to anticancer drug 6-Mercaptopurine (6-MP) by structure and ligand-based virtual screening
por: Chen, Ya, et al.
Publicado: (2018) -
Role of CC-chemokine ligand 2 in gynecological cancer
por: Zhang, Jia-Jia, et al.
Publicado: (2022) -
CC Chemokine Ligand 18 Correlates with Malignant Progression of Prostate Cancer
por: Chen, Guo, et al.
Publicado: (2014) -
Design and Characterization of an Intracellular Covalent Ligand for CC
Chemokine Receptor 2
por: Ortiz Zacarías, Natalia V., et al.
Publicado: (2021)